Sudarshan Pharma Industries promoters Hemal V Mehta and Sachin V Mehta created a pledge on 6,60,000 equity shares each on August 20, 2026. The encumbrance serves as security for loans taken by the company.

The pledge covers 2.64% of the total share capital for each promoter. Satin Finserv Limited is the entity in whose favor the shares were encumbered.

Pledge Details

Both promoters reported no prior encumbrances on their holdings before this transaction. The creation of these pledges was disclosed to BSE Limited on August 21, 2026, in compliance with Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Hemal V Mehta holds 6,85,21,020 shares (27.44%), while Sachin V Mehta holds 7,07,05,470 shares (28.32%). The post-event holding of encumbered shares stands at 6,60,000 for both individuals.

Sudarshan Pharma Industries reported a significant improvement in profitability for the first quarter of FY27, with net profit after tax (PAT) rising 41.6% year-on-year to ₹5.61 crore. The pharmaceutical and specialty chemicals manufacturer achieved this growth against a backdrop of expanding revenues and improving operational margins, marking a strong start to the fiscal year following a full-year PAT growth of 102% in FY26.

Revenue from operations increased 20.1% to ₹174.41 crore in June 2026, compared to ₹145.26 crore in the same period last year. This top-line growth was accompanied by a notable expansion in gross profit margin, which widened to 14.13% from 11.05% in Q1FY26. The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) rose 39.7% to ₹17.11 crore, with the EBITDA margin improving to 9.81% from 8.43% previously.

Financial Performance

The consolidated financial results for the quarter highlight consistent growth across key metrics compared to the prior year period. Finance costs remained elevated at ₹8.20 crore, up from ₹5.96 crore in Q1FY26, reflecting higher borrowing levels to support expansion initiatives.

For the full year FY26, Sudarshan Pharma logged revenue of ₹703.05 crore, a 39.2% increase over FY25’s ₹505.05 crore. Full-year PAT surged 102% to ₹23.41 crore from ₹11.59 crore in the preceding year, demonstrating sustained operational momentum throughout the fiscal cycle.

What the Numbers Show

A critical observation from the balance sheet is the substantial increase in leverage alongside revenue growth. Short-term borrowings rose sharply to ₹255.11 crore as on March 31, 2026, from ₹160.27 crore a year earlier. Concurrently, long-term borrowings increased to ₹38.37 crore from ₹10.46 crore. This debt accumulation appears linked to capital expenditure, as property, plant, and equipment assets nearly tripled to ₹96.03 crore from ₹29.91 crore. While revenue grew robustly, the finance cost of ₹8.20 crore in Q1FY27 consumed approximately 148% of the operating EBITDA, indicating that debt servicing remains a significant pressure point on bottom-line retention despite margin improvements.

Strategic Initiatives

The company outlined its strategic focus for FY27-28, emphasizing vertical integration and expansion into regulated markets. Sudarshan Pharma aims to strengthen its presence in semi-regulated and regulated segments, targeting an export turnover of at least ₹100 crore in FY27. The firm plans to increase its range of high-value Active Pharmaceutical Ingredients (APIs) to boost exports to Europe and the USA.

Key operational developments include:

• Hyderabad Unit: A new bulk drug and intermediate manufacturing facility has secured Good Manufacturing Practice (GMP) certification for API intermediates and ISO 9001:2015 for quality management. The unit holds patent rights for several key starting materials.
• R&D Collaboration: A strategic partnership with Amity University focuses on nanotechnology, pharmaceutical R&D, and patent filings, led by Dr. William Selvamurthy.
• Product Portfolio: Expansion into oncology APIs such as Gemcitabine and Olaparib, alongside new chemical sector products like 1,4-Dioxane and Acetonitrile.

The investor presentation, submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, highlights the company’s efforts to mitigate supply chain dependencies on China by developing domestic manufacturing capabilities for specialty chemicals and intermediates.